Skip to main content
Premium Trial:

Request an Annual Quote

Panel Votes for COVID-19 Pill

An advisory panel to the US Food and Drug Administration has voted 13 to 10 to support the emergency use authorization of an antiviral pill from Merck and Ridgeback Biotherapeutics to treat COVID-19, CNN reports.

In October, the companies reported initial data that the drug, molnupiravir, which is taken orally as four capsules twice a day for five days, reduced the risk of hospitalization or death among high-risk COVID-19 patients by 50 percent, as compared to placebo. But a final analysis released last week suggested instead that molnupiravir reduced the risk of hospitalization and death by 30 percent.

NPR notes that panelists discussed potential safety concerns of the treatment, particularly worries that it could lead to mutations beyond the virus and cause birth defects.

"I voted yes because COVID-19 is still an emergency situation. As a frontline clinician in treating patients, both inpatient and outpatient, there is a need for something like this," W. David Hardy from the Charles Drew University School of Medicine and Science, tells CNN. He adds that he does still have "questions about its overall, longer term efficacy."

NPR notes that the FDA generally, but not always, follows the recommendations of its advisory panels and that if it authorizes molnupiravir, it would be the first oral medication for COVID-19.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.